Page last updated: 2024-12-06

fucopyranosyl phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fucopyranosyl phosphate: structure given in first source; RN given for (beta-L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beta-L-fucose 1-phosphate : The beta-anomer of L-fucose 1-phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65369
CHEBI ID12387
SCHEMBL ID1065994
MeSH IDM0216672

Synonyms (27)

Synonym
fucopyranosyl phosphate
6-deoxy-beta-l-galactopyranose 1-(dihydrogen phosphate)
beta-l-fucopyranose 1-(dihydrogen phosphate)
28553-11-9
fucose 1-phosphate
CHEBI:12387
6-deoxy-1-o-phosphono-beta-l-galactopyranose
C02985
beta-l-fucose 1-phosphate
[(2r,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl] dihydrogen phosphate
fucose, 1-(dihydrogen phosphate), beta-l-
beta-l-fucopyranosyl dicyclohexylammonium phosphate
16562-59-7
SCHEMBL1065994
b-l-fucose 1-phosphate
(3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl)oxyphosphonate
b-l-fucose-1-phosphate
beta-l-fucose-1-phosphate
(2r,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl dihydrogen phosphate
beta-l-fucose 1-phosphate di(cyclohexylammonium salt)
Q27108953
beta-l-galactopyranose, 6-deoxy-, 1-(dihydrogen phosphate)
HY-145781
DTXSID501310005
beta-l-fucopyranosyl phosphate
CS-0432869
{[(2r,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}phosphonic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
L-fucopyranose 1-phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
Metabolism of proteins1058144
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein5068
Synthesis of substrates in N-glycan biosythesis3756
GDP-fucose biosynthesis616
Fructose and Mannose metabolism ( Fructose and Mannose metabolism )2527
GTP + L-Fucose 1-phosphate = GDP-L-fucose + Pyrophosphate ( Fructose and Mannose metabolism )14

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (70.00)18.2507
2000's1 (10.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]